Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.69 USD
−86.62 M USD
22.60 M USD
27.84 M
About Foghorn Therapeutics Inc.
Sector
Industry
CEO
Adrian Gottschalk
Website
Headquarters
Cambridge
Founded
2015
FIGI
BBG00HFZPB88
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
NVDA-Backed Breakout or Just Hype? Boom or Bust Play!FHTX is showing strong bullish momentum, recently forming a key gap at the $4.00 level, signaling fresh buying interest and accumulation. This setup suggests potential for continuation, as the stock builds strength for its next major move.
Adding to the bullish case, NVIDIA (NVDA) has been supporti
$FHTX is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
Foghorn Therapeutics is a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system.
The share price is rising and gonna continue this trend today.
The demand
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where FHTX is featured.

Mid-weight oncology stocks: The dark horses of cancer research
18 No. of Symbols
See all sparks
Related stocks
Frequently Asked Questions
The current price of FHTX is 4.37 USD — it has decreased by −4.49% in the past 24 hours. Watch Foghorn Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Foghorn Therapeutics Inc. stocks are traded under the ticker FHTX.
FHTX stock has risen by 29.57% compared to the previous week, the month change is a 6.43% rise, over the last year Foghorn Therapeutics Inc. has showed a −13.29% decrease.
We've gathered analysts' opinions on Foghorn Therapeutics Inc. future price: according to them, FHTX price has a max estimate of 18.00 USD and a min estimate of 9.00 USD. Watch FHTX chart and read a more detailed Foghorn Therapeutics Inc. stock forecast: see what analysts think of Foghorn Therapeutics Inc. and suggest that you do with its stocks.
FHTX reached its all-time high on Dec 18, 2020 with the price of 28.27 USD, and its all-time low was 2.70 USD and was reached on Feb 5, 2024. View more price dynamics on FHTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
FHTX stock is 7.33% volatile and has beta coefficient of 1.65. Track Foghorn Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Foghorn Therapeutics Inc. there?
Today Foghorn Therapeutics Inc. has the market capitalization of 248.59 M, it has increased by 10.14% over the last week.
Yes, you can track Foghorn Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Foghorn Therapeutics Inc. is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
FHTX earnings for the last quarter are −0.23 USD per share, whereas the estimation was −0.31 USD resulting in a 26.48% surprise. The estimated earnings for the next quarter are −0.35 USD per share. See more details about Foghorn Therapeutics Inc. earnings.
Foghorn Therapeutics Inc. revenue for the last quarter amounts to 2.86 M USD, despite the estimated figure of 7.20 M USD. In the next quarter, revenue is expected to reach 5.81 M USD.
FHTX net income for the last quarter is −19.50 M USD, while the quarter before that showed −19.12 M USD of net income which accounts for −1.99% change. Track more Foghorn Therapeutics Inc. financial stats to get the full picture.
No, FHTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 25, 2025, the company has 112 employees. See our rating of the largest employees — is Foghorn Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Foghorn Therapeutics Inc. EBITDA is −97.19 M USD, and current EBITDA margin is −429.90%. See more stats in Foghorn Therapeutics Inc. financial statements.
Like other stocks, FHTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Foghorn Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Foghorn Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Foghorn Therapeutics Inc. stock shows the sell signal. See more of Foghorn Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.